Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care

被引：17
|
作者：
Packer, Milton [1 ,2 ]
机构：
[1] Baylor Univ, Med Ctr, Baylor Heart & Vasc Inst, Dallas, TX USA
[2] Imperial Coll, London, England
来源：
EUROPEAN HEART JOURNAL | 2020年 / 41卷 / 25期
关键词：
CANAGLIFLOZIN; METFORMIN;
D O I：
10.1093/eurheartj/ehaa344
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：2393 / 2396
页数：4
相关论文
共 10 条
  • [1] SGLT2 inhibitors: What role do they play in heart failure with reduced ejection fraction?
    Lenahan, Christy McDonald
    Harrington, Deedra
    Stueben, Frances
    NURSE PRACTITIONER, 2021, 46 (07): : 30 - 37
  • [2] SGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction
    Silva-Cardoso, Jose
    Andrade, Aurora
    Brito, Dulce
    Ferreira, Jorge
    Fonseca, Candida
    Peres, Marisa
    Franco, Fatima
    Moura, Brenda
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2021, 40 (09) : 687 - 693
  • [3] Beyond the myocardium? SGLT2 inhibitors target peripheral components of reduced oxygen flux in the diabetic patient with heart failure with preserved ejection fraction
    Mouhamed Nashawi
    Omar Sheikh
    Ayman Battisha
    Mahnoor Mir
    Robert Chilton
    Heart Failure Reviews, 2022, 27 : 219 - 234
  • [4] Beyond the myocardium? SGLT2 inhibitors target peripheral components of reduced oxygen flux in the diabetic patient with heart failure with preserved ejection fraction
    Nashawi, Mouhamed
    Sheikh, Omar
    Battisha, Ayman
    Mir, Mahnoor
    Chilton, Robert
    HEART FAILURE REVIEWS, 2022, 27 (01) : 219 - 234
  • [5] Chapter 2: Clinical and Mechanistic Potential of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors in Heart Failure with Preserved Ejection Fraction
    Ostrominski, John W.
    Vaduganathan, Muthiah
    AMERICAN JOURNAL OF MEDICINE, 2024, 137 (02): : S9 - S24
  • [6] Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction
    Pandey, Arjun K.
    Bhatt, Deepak L.
    Pandey, Avinash
    Marx, Nikolaus
    Cosentino, Francesco
    Pandey, Ambarish
    Verma, Subodh
    EUROPEAN HEART JOURNAL, 2023, 44 (37) : 3640 - 3651
  • [7] SGLT2 Inhibitors' Cardiovascular Benefits in Individuals Without Diabetes, Heart Failure, and/or Chronic Kidney Disease: A Systematic Review
    Khiali, Sajad
    Taban-Sadeghi, Mohammadreza
    Sarbakhsh, Parvin
    Khezerlouy-Aghdam, Naser
    Rezagholizadeh, Afra
    Asham, Hila
    Entezari-Maleki, Taher
    JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (12): : 1307 - 1323
  • [8] Expanded use of sodium-glucose cotransporter 2 inhibitors: Evidence beyond heart failure with reduced ejection fraction
    Schoenborn, Erika Michelle
    Skersick, Preston Trudell
    Thrasher, Claire Maxine
    Page, Robert L.
    PHARMACOTHERAPY, 2023, 43 (09): : 950 - 962
  • [9] Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors Potential Role in Mediating the Heart Failure Benefits of SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors
    Packer, Milton
    CIRCULATION-HEART FAILURE, 2020, 13 (09) : E007197
  • [10] Combining sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors in heart failure patients with reduced ejection fraction and diabetes mellitus: A multi-institutional study
    Hsiao, Fu-Chih
    Lin, Chia-Pin
    Tung, Ying-Chang
    Chang, Po-Cheng
    McMurray, John J., V
    Chu, Pao-Hsien
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 330 : 91 - 97
1